Biologictreatment* / Dose / Trial / Number of patients / ACR20 response / ACR50 response / ACR70 response / Reference
Abatacept / 10mg/kg per month / NA / 339 / 60% / 36% / 16% / Kremer etal. (2003)1
Adalimumab / 40mg every 2weeks / ARMADA / 271 / 67% / 55% / 27% / Weinblatt etal. (2003)2
Certolizumab / 200mg every 2weeks / RAPID 1 / 982 / 53% / 38% / 21% / Keystone etal. (2008)3
Etanercept / 25mg twice a week / NA / 234 / 59% / 40% / 14% / Moreland etal. (1999)4
Golimumab / 50mg per month / GO-FORWARD / 444 / 60% / 38% / 18% / Keystone etal. (2009)5
Infliximab / 3mg/kg every 8wk / ATTRACT‡ / 428 / 50% / 27% / 8% / Maini etal. (1999)6
Rituximab / 2 pulses of 1000mg / DANCER / 465 / 54% / 34% / 20% / Emery etal. (2006)7
Tocilizumab / 8mg/kg every month / OPTION / 622 / 59% / 44% / 22% / Smolen etal. (2008)8
Oral Syk inhibitor
Fostamatinib / 100mg twice daily / NA / 457 / 66% / 43% / 28% / Weinblatt etal. (2010)9
*Biologic agents are presented in alphabetical order. ‡Clinical assessment at 30weeks. Abbreviation: ACR20/50/70, AmericanCollege of Rheumatology criteria for 20%/50%/70% improvement; NA, not applicable; Syk, spleen tyrosine kinase.
1.Kremer, J.M. etal. Treatment of rheumatoid arthritis by selective inhibition of Tcell activation with fusion protein CTLA4Ig. N. Engl. J. Med.349, 1907–1915 (2003).
2.Weinblatt, M.E. etal. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48, 35–45 (2003).
3.Keystone, E. etal. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fiftytwoweek, phaseIII, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum.58, 3319–3329 (2008).
4.Moreland, L.W. etal. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med.130, 478–486 (1999).
5.Keystone, E.C. etal. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD Study. Ann. Rheum. Dis.68, 789–796 (2009).
6.Maini, R. etal. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phaseIII trial. ATTRACT Study Group. Lancet354, 1932–1939 (1999).
7.Emery, P. etal. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phaseIIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum.54, 1390–1400 (2006).
8.Smolen, J.S. etal. Effect of interleukin6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet371, 987–997 (2008).
9.Weinblatt, M.E. etal. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med.363, 1303–1312 (2010).
1